Australia TGA ARTG recordJuvederm VOLITE - Synthetic-fluid tissue reconstructive material, anaesthetic
Australia TGA ARTG Registered Device · Abbvie Pty Ltd · Allergan · Class III · Started August 13, 2018
Good Name: Abbvie Pty Ltd - Juvederm VOLITE - Synthetic-fluid tissue reconstructive material, anaesthetic
- Risk Class
- Class III
- Product Type
- Single Device Product
- ARTG Category
- General
- Start Date
- August 13, 2018
- Effective Date
- August 13, 2018
- Name
- Abbvie Pty Ltd
- Name
- Allergan
- Country
- France
- Address
- Route de Promery , Zone Artisanale de Pre Mairy, Pringy, Annecy, 74370
Juvéderm® VOLITE™ is an injectable implant used for the treatment, by filling, of superficial cutaneous depressions such as fine lines and for additional improvement of skin quality attributes such as hydration and elasticity, via intradermal injection. The presence of lidocaine is meant to reduce the patient’s pain during treatment.
Access comprehensive regulatory information for Juvederm VOLITE - Synthetic-fluid tissue reconstructive material, anaesthetic in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is sponsored by Abbvie Pty Ltd, manufactured by Allergan in France. The device registration started on August 13, 2018.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.